ICCM is trading at 5% up now at $5.55 in pre-market, extending a sharp rebound after recent volatility and prior multi-bagger gains tied to optimism around its ProSense cryoablation platform and recent FDA clearance.[1][3] No fresh company-specific news or earnings items have appeared so far on July 2, 2026; the move looks like continued speculative trading in a highly volatile small-cap biotech rather than a reaction to new headlines.[1][2][3]